This approach not only effectively primed CD8+ and CD4+ T cells within the body but also facilitated the ex vivo expansion of these reactive T lymphocytes, which were subsequently reintroduced into the patient’s system to efficiently target and eliminate tumor cells [111]. This evidence concerns the gene CD4 and neoplasm.